Oxford Biomedica - Edison Group

Overview
Price performance
Financials
Research
Thematics

Oxford Biomedica is a UK-based company with a leading position in cancer immunotherapy and gene-based products. It is focusing its efforts on two clinical programmes, ProSavin and TroVax, and has an ocular collaboration with Sanofi-Aventis.

Latest Insights

View More

Healthcare |
Flash note

05.07.22

Oxford Biomedica — COVID vaccine and Kymriah news encouraging

Healthcare |
edison tv

09.02.22

Oxford Biomedica: Edison Open House Healthcare 2022

Healthcare |
Outlook

27.05.21

Oxford Biomedica — Driving innovation in a thriving CGT industry

Healthcare |
edison tv

24.02.21

Oxford Biomedica – executive interview

Sector

Healthcare

Balance Sheet

Forecast net debt (£m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	4.4	46.0	(42.4)
Relative	1.7	35.1	(43.6)
52 week high/low	808.0p/297.0p

Financials

Oxford Biomedica (OXB) announced that it has signed a new three-year Master Services and Development Agreement with AstraZeneca (AZN) for future production of the AZN COVID-19 vaccine. As an expansion of the original agreement signed in September 2020, AZN will now have access to OXB’s world-class Oxbox manufacturing facilities on an as-needed basis from the start of 2023. Management expects revenues of approximately £30m from AZN in FY22 for batches of the vaccine already manufactured in 2022 under the original agreement. In addition, Novartis recently announced encouraging five-year follow-up data from the ELIANA clinical trial investigating the use of Kymriah in the treatment of relapsed or refractory (r/r) B-cell acute lymphoblastic leukaemia (ALL). OXB is the sole global supplier of lentiviral vector for Kymriah. We view both announcements as a positive for OXB’s future revenues. Our valuation and forecasts are currently under review.

Y/E Dec	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2020A	87.7	8.3	(2.5)	(2.7)	N/A	23.2
2021A	142.8	33.2	19.9	22.2	20.7	13.1
2022E	N/A	N/A	N/A	N/A	N/A	N/A
2023E	N/A	N/A	N/A	N/A	N/A	N/A

Research

Update

Healthcare

06.02.20

Oxford Biomedica — OxBox investment to aid future growth

Update

Healthcare

19.12.19

Oxford BioMedica — Novartis extends commercial supply agreement

Healthcare

Update

Oxford BioMedica — Juno deal expands CAR-T revenue streams

Update

Healthcare

01.10.19

Oxford Biomedica — Investing for future growth

Flash note

Healthcare

05.09.19

Oxford Biomedica — Burgeoning bioprocessing revenues

Flash note

Healthcare

26.06.19

Oxford BioMedica — Santen – a global player in ophthalmology

Outlook

Healthcare

04.06.19

Oxford Biomedica — In a cell and gene therapy sweet spot

Update

Healthcare

09.11.18

Oxford BioMedica — Diversified strategy showing its strength

Update

Healthcare

08.06.18

Oxford BioMedica — Golden age for LentiVector as Axovant signs deal

Outlook

Healthcare

10.05.18

Oxford BioMedica — Validation achieved, growth expected

Flash note

Healthcare

16.02.18

Oxford BioMedica — LentiVector platform expanding into haemophilia

Update

Healthcare

25.07.17

Oxford BioMedica — CTL019 approval likely in pALL, ad-com positive

Flash note

Healthcare

06.07.17

Oxford BioMedica — Lentiviral vector supply for CTL019 driving revenue growth

Update

Healthcare

05.04.17

Oxford BioMedica — CTL019 and product out-licensing to drive 2017

Flash note

Healthcare

05.12.16

Oxford BioMedica — Update 5 December 2016

Update

Healthcare

02.12.16

Oxford BioMedica — Update 2 December 2016

Outlook

Healthcare

24.10.16

Oxford BioMedica — Update 24 October 2016

thematic

Healthcare

13.06.23

ASCO 2023 key takeaways

thematic

Healthcare

26.01.23

Machine learning in drug development

thematic

Healthcare

06.01.23

Outlook for 2023: Biotechs remain central to novel drug development

Cancer cells

thematic

Healthcare

04.01.23

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

cell DNA double helix

thematic

Healthcare

20.12.22

Cell and gene therapies

thematic

Healthcare

28.11.22

Drug delivery platforms

thematic

Healthcare

07.11.22

Oncology ABCs (part three) – thinking outside the box in women’s cancer

thematic

Healthcare

01.11.22

Neuroscience comeback

thematic

Consumer

05.10.22

IPO apocalypse

thematic

Healthcare

03.10.22

Oncology ABCs (part two) – vaccines: niche no longer

thematic

TMT

10.08.22

ESG, moving beyond the box tick

thematic

Healthcare

01.07.22

Oncology ABCs (part one) – a small-cap biopharma prospectus series

thematic

Healthcare

26.04.22

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

thematic

Healthcare

10.11.21

Artificial intelligence in drug discovery

thematic

Healthcare

27.07.21

Biosynthesis – Taking the cannabinoid market to new heights

thematic

Healthcare

22.03.21

Seven things every investor should know about SIGA technologies & biological weapons

thematic

Healthcare

01.02.21

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

thematic

Healthcare

30.10.19

Edison Exhibits- antibiotic development

thematic

Healthcare

17.07.19

The next wave in AMD

thematic

Healthcare

18.06.19

The A-B-T of biosimilars- Explaining contemporary life science issues

thematic

Healthcare

10.06.19

Cannabinoid Therapies- The coming retail wave

thematic

Healthcare

22.05.19

Cannabinoid Therapies- Therapeutics turning a corner

thematic

Healthcare

08.04.19

Trial outcomes and value – Explaining contemporary clinical trial issues

thematic

Healthcare

04.03.19

Drug pricing – Market access and reimbursement

thematic

Healthcare

29.01.19

The diagnostics sector

thematic

Healthcare

21.06.17

ASCO 2017

thematic

Consumer

11.11.14

Deutsche Börse Eigenkapitalforum 2014 Research Guide

thematic

Healthcare

05.03.14

Edison healthcare quarterly: A boost for allergy immunotherapy

thematic

Energy & Resources

04.03.14

ASX Spotlight Conference – London, 6 March 2014

thematic

Energy & Resources

01.03.13

ASX Small to Mid Caps Conference – London, 7 March 2013

thematic

Healthcare

07.12.12

Edison healthcare quarterly: Boom times for US biotech

thematic

Healthcare

30.08.12

Edison healthcare quarterly: Crisis? What crisis?

thematic

Healthcare

28.05.12

Edison healthcare quarterly: How to please some of the people some of the time